Aprovel irbesartan regulatory update

EMA's CHMP recommended updating the labels of hypertension drugs Aprovel irbesartan and CoAprovel irbesartan/hydrochlorothiazide to include a contraindication for patients with diabetes or moderate to severe renal impairment